Current Trials

Early-Stage (II to IIIA) Non-small Cell Lung Cancer

The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab.

IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy.

The purpose of this study is to learn more about the safety and efficacy of the medication
ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who
are presenting a particular gene mutation called IDH1 (isocitrate dehydrogenase1
mutation-positive [IDH1m]) and cannot receive treatment with intensive chemotherapy (IC).

Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.

Cancer Associated Venous Thromboembolism

The purpose of this study is to compare the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE.

PD-L1 Metastatic NSCLC

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

High-risk early triple negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene. For this study high-risk early TNBC is defined as any presence of TNBC that still remains in the breast or lymph node tissue after receiving treatment and undergoing surgery.

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in patients with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.

Blood Cancer

Healthy Volunteers for Research and Development Purpose

Clinical Haematology Patients

Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of the study is to compare the efficacy of Nivolumab and Relatlimab Plus Chemotherapy Vs Pembrolizumab Plus Chemo for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

No new patients will be recruited to this study. The original study involved patients with breast cancer treated with Trastuzumab.If you participated in the CTRIAL-IE (ICORG) 08-01 CADY study on cardiac dysfunction in HER-2 positive breast cancer patients, please read this important data protection notice. Cancer Trials Ireland, in collaboration with Abbott Laboratories, is conducting a follow-up sub-study to re-test stored biological samples using advanced biomarker technology and review medical records for cardiovascular outcomes. This research aims to improve early detection of heart risks in breast cancer patients treated with Trastuzumab. Your data remains securely stored and protected, with strict access controls. If you wish to learn more, withdraw consent, or exercise your data rights, click here to read the full notice.

The study aims to:
(1) Evaluate the predictive capability of chosen cardiac biomarkers in forecasting cardiac dysfunction in breast cancer patients treated with Trastuzumab.
(2) Develop a predictive model using machine learning techniques based on the most accurate and sensitive combination of biomarkers.

ER+/HER2- early breast cancer with intermediate-high or high risk of recurrence

The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant +/- abemaciclib as compared to standard endocrine therapy +/- abemaciclib by assessment of invasive breast cancer-free survival

Patients with histologically proven adenocarcinoma of the GEJ type II

The objective of this study is to compare transthoracic esophagectomy versus transhiatal extended gastrectomy inpatients in patients with adenocarcinoma of the gastroesophageal junction (GEJ) type II

All cancers (including metastatic), with the exception of brain cancers.

To assess the safety and effectiveness of a new medication in cancer patients with anorexia and weight loss.